Clinical Report: Investigating the Link Between Inflammation and Neurodegeneration

Overview

This pilot study explores the integration of inflammatory and neurodegenerative biomarkers to distinguish between relapsing and secondary progressive multiple sclerosis (MS). The findings indicate that a combination of serum neurofilament light chain, retinal layer thickness, and monocyte subsets can accurately predict disease progression, achieving approximately 80% classification accuracy.

Background

Multiple sclerosis (MS) is characterized by a complex interplay of inflammation and neurodegeneration, which complicates diagnosis and treatment strategies. Identifying biomarkers that can predict disease progression independent of relapse activity is crucial for improving patient outcomes. This study addresses the urgent need for reliable diagnostic tools that can differentiate between relapsing MS and secondary progressive MS.

Data Highlights

Key Findings

• Significant thinning of RNFL and GCIPL observed in SPMS compared to RMS.
• Functional mfERG readouts did not differ significantly between MS subgroups.
• Elevated levels of sNfL and GFAP in pwMS, with higher levels in SPMS.
• Increased frequency of non-classic and intermediate monocytes in SPMS.
• CART model achieved approximately 80% accuracy in distinguishing RMS from SPMS.

Clinical Implications

The integration of neurodegenerative and inflammatory biomarkers could enhance diagnostic accuracy for MS progression. Clinicians may consider utilizing these biomarkers to identify patients at risk of transitioning from relapsing to progressive forms of MS, allowing for timely therapeutic interventions.

Conclusion

This study provides a promising framework for differentiating between RMS and SPMS through a multimodal biomarker approach. Further validation in larger cohorts is necessary to establish clinical applicability.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Source, Year -- Title
3. Author(s)/Org, Source, Year -- Title
4. Author(s)/Org, Source, Year -- Title
5. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria - PubMed
6. Toward a Unified Definition of Progression Independent of Relapse Activity in Multiple Sclerosis | Neurology
7. Frontiers | Disease-modifying therapy in progressive multiple sclerosis: a systematic review and network meta-analysis of randomized controlled trials
8. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria - PubMed
9. Toward a Unified Definition of Progression Independent of Relapse Activity in Multiple Sclerosis | Neurology
10. Frontiers | Disease-modifying therapy in progressive multiple sclerosis: a systematic review and network meta-analysis of randomized controlled trials